Press coverage about Amyris (NASDAQ:AMRS) has been trending somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amyris earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.7095444488477 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:

AMRS has been the subject of several recent research reports. Zacks Investment Research raised Amyris from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 16th. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Amyris in a report on Tuesday, May 23rd. ValuEngine cut Amyris from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Finally, Cowen and Company set a $4.00 price objective on Amyris and gave the stock a “hold” rating in a report on Thursday, August 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. Amyris has an average rating of “Hold” and an average target price of $30.25.

Shares of Amyris (NASDAQ:AMRS) traded up 14.73% during mid-day trading on Wednesday, hitting $3.66. The stock had a trading volume of 397,794 shares. Amyris has a 1-year low of $0.21 and a 1-year high of $18.15. The firm’s market capitalization is $137.64 million. The stock’s 50-day moving average is $2.92 and its 200-day moving average is $4.97.

Amyris (NASDAQ:AMRS) last issued its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($1.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.06) by ($0.35). The firm had revenue of $25.68 million during the quarter, compared to the consensus estimate of $23.68 million. During the same period last year, the business earned ($0.06) EPS. Amyris’s revenue was up 167.5% compared to the same quarter last year. Equities analysts expect that Amyris will post ($3.32) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at

Amyris Company Profile

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Insider Buying and Selling by Quarter for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.